Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.38 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 2/20 | 0.38 |
| ▸ | IGF1R | P08069 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GRK2 | P25098 | 1/20 | 0.37 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL827695 | 0.92 | GABBR2 (0.42) | KMT2AMEN1LMNAHTTSMN1; SMN2 | |
| SCHEMBL826594 | 0.85 | GMNN (0.48) | EGFRERBB2LMNAPPARGPPARA | |
| SCHEMBL828089 | 0.85 | KMT2A (0.50) | KMT2AMEN1LMNAHTTGABBR2 | |
| SCHEMBL828011 | 0.82 | KMT2A (0.56) | EGFRERBB2KMT2AMEN1LMNA | |
| SCHEMBL5132112 | 0.79 | KMT2A (0.47) | EGFRERBB2KMT2AMEN1LMNA | |
| SCHEMBL12237257 | 0.79 | HSD11B1 (0.48) | EGFRERBB2KMT2AMEN1LMNA | |
| SCHEMBL5049918 | 0.73 | EGFR (0.45) | EGFRERBB2KMT2AMEN1LMNA | |
| SCHEMBL827092 | 0.73 | KMT2A (0.48) | KMT2AMEN1SMN1; SMN2POLBAOC3 | |
| SCHEMBL824466 | 0.73 | HPGD (0.54) | KMT2AMEN1LMNAAOC3 | |
| SCHEMBL8497178 | 0.72 | SMN1; SMN2 (0.44) | KMT2AMEN1LMNAHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090124828-A1 | Unsaturated Sulfides, Sulfones, Sulfoxides and Sulfonamides Synthesis | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2009-05-14 | — | — | US | claimed |
| EP-1896401-A2 | UNSATURATED SULFIDES, SULFONES, SULFOXIDES AND SULFONAMIDES SYNTHESIS | Temple University of the Commonwealth System of Higher Education (US) | 2008-03-12 | — | — | EP | claimed |
| WO-2006091870-A2 | UNSATURATED SULFIDES, SULFONES, SULFOXIDES AND SULFONAMIDES SYNTHESIS | TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2006-08-31 | — | — | WO | claimed |
| EP-1896401-B1 | UNSATURATED SULFIDES, SULFONES, SULFOXIDES AND SULFONAMIDES SYNTHESIS | UNIV TEMPLE (US) | 2013-04-10 | — | — | EP | disclosed |
| US-8143453-B2 | Unsaturated sulfides, sulfones, sulfoxides and sulfonamides synthesis | Temple University—Of the Commonwealth System of Higher Education (US) | 2012-03-27 | — | — | US | disclosed |
| US-20090124828-A1 | Unsaturated Sulfides, Sulfones, Sulfoxides and Sulfonamides Synthesis | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2009-05-14 | — | — | US | disclosed |
| EP-1896401-A2 | UNSATURATED SULFIDES, SULFONES, SULFOXIDES AND SULFONAMIDES SYNTHESIS | Temple University of the Commonwealth System of Higher Education (US) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006091870-A2 | UNSATURATED SULFIDES, SULFONES, SULFOXIDES AND SULFONAMIDES SYNTHESIS | TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124828-A1 | Unsaturated Sulfides, Sulfones, Sulfoxides and Sulfonamides Synthesis | SULT2A1, SULT1A1, ARSA | EGFR 1291/4885ERBB2 2014/4885KMT2A 2578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.